Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector T cells

A technology of stem cells and cells, applied in the field of cancer immunotherapy, can solve problems such as lack of

Inactive Publication Date: 2017-09-08
AGENCY FOR SCI TECH & RES
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a limitation in developing this strategy is the lack of sufficient amount of tumor cells to provide tumor-specific antigen (tumor-specific antigen, TSA) and tumor-associated antigen (tumor-associated antigen) for activation of immune system cells against CRC cells. , TAA)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector T cells
  • A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector T cells
  • A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector T cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] Example 1 Materials and Methods

[0090] Zinc finger nuclease technology was used to insert a group of cellular reprogramming factors called OSKM factors (Oct4, Sox2, Klf4 and cMyc) into the genome of CRC cells for the induced reprogramming of these cancer cells. CSC-like cells were enriched from reprogrammed CRC cells using a tumorsphere formation method. These CSC-like cells consistently showed up-regulated expression of CD24 and many other colorectal CSC-associated antigens. These CSC-like cells were then used for dendritic cell (DC) vaccination, which has been tested as an adjuvant therapy for CRC. After sensitization of autologous naive T cells with DCs pulsed with OSKM-expressing CRC cell lysate, T cells were detected in an IFN-γ EliSpot assay by restimulation with T2 cells loaded with CSC antigen-related peptides. Significantly increased IFN-γ positive puncta demonstrated that pulsed DCs were able to elicit anti-CSC antigen responses in autologous T cells. Thu...

Embodiment 2

[0118] Generation of colorectal cancer iPC cells by stably expressing the OSKM gene

[0119] An engineered zinc finger nuclease (ZFN) technology based on baculovirus transduction was recently developed for site-specific integration of OSKM factor genes (Phang et al., 2013). This technique involves the use of two non-integrating baculovirus vectors: one expressing ZFN (BV-ZFN) and the other encoding the OSKM transcription factor gene (BV-OSKM) as a donor vector. BV-OSKM carries an expression cassette containing the human Oct4, Klf4, Sox2 and c-Myc genes linked to the self-cleaving 2A sequence and IRES as fusion genes and driven by the EF1a promoter. The expression cassette is flanked by sequences homologous to the AAVS1 locus. After co-transduction with BV-ZFN and BV-OSKM ( figure 1 A), the expression cassette can be efficiently introduced into the AAVS1 locus in human chromosome 19, which is the opening of insulator elements flanking the integrated transgene to protect the i...

Embodiment 3

[0122] Ectopic expression of OSKM confers CSC-like properties to human CRC cells

[0123] HCT8 and SW480 derived iPC cells were expanded in CSC medium consisting of a 1:1 mixture of DMEM / F12 supplemented with 1% FBS and 20 ng / ml human epidermal growth factor (EGF). Using the RTqPCR method, the relative expression levels of the OSKM gene in the selected clones were determined ( figure 2 A). An 8- to 400-fold overexpression of Sox2 was observed in all HCT8 and SW480 clones examined compared to wild-type (WT) cells. A 2- to 100-fold upregulation of Oct4 was observed in 4 of the 5 clones examined. Western blot analysis confirmed up-regulated expression of Oct4 and Sox2 proteins in these clones. The upregulation of c-Myc and Klf4 was less pronounced, probably because of the high level of expression of endogenous genes in HCT8 and SW480CRC subclones.

[0124]An attempt was made to elucidate the role of ectopic expression of the OSKM gene in the phenotypic characteristics of CSC...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention concerns a method of preparing a composition comprising stimulated immune system cells such as dendritic cells (DC) for use in inducing immune response of cytotoxic T lymphocytes against colorectal cancer. The dendritic cells are pulsed by contact with colorectal cancer stem cells (CSC) or their fragments thereof. These colorectal CSCs are produced by OSKM (Oct4, Sox2, Klf4 and c-Myc) induced reprogramming of differentiated colorectal cancer cells (CRC) which results in undifferentiated colorectal CSC-like cells. Both the CSC-like cells and the lysates of heat-shocked CSC-like cells could be used as an accessible source of tumour antigens for DC pulsing to induce specific immune responses against colorectal CSCs.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims the benefit of priority from Singapore Patent Application No. 10201405497U filed on September 4, 2014, the contents of which are hereby incorporated by reference in their entirety for all purposes. technical field [0003] The present invention generally relates to cancer immunotherapy. In particular, the present invention relates to the use of reprogrammed colorectal cancer stem cells to activate immune system cells against cancer cells. Background technique [0004] Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide and is the second or third leading cause of cancer-related mortality in many industrialized countries. More than 50% of patients initially diagnosed with localized CRC eventually develop stage IV CRC with distant metastasis or recurrence. Small subsets of highly tumorigenic (or tumor-initiating) cells (ie, colorectal cancer stem cells (CSCs)) have been...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0784C12N5/095A61K35/15A61K39/00A61P35/00
CPCA61K39/0011A61K35/15A61K2039/5154A61K2039/572C12N5/0695C12N5/0696C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2502/30C12N2502/45C12N2506/30C12N5/0639A61P35/00
Inventor 王朔吴春晓曾洁铭Y·I·普尔瓦提邱锦标
Owner AGENCY FOR SCI TECH & RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com